LYT-100 is a deuterated form of pirfenidone and an inhibitor of proinflammatory mediators, such as TNF-α, TGF-β, and IL-6, and is being studied for diseases that are associated with inflammatory and fibrotic pathologies, including lymphedema [184] and IPF [185]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.